Target intelligence / Profile preview

Cytochrome P450 family 4 subfamily F member 12 (CYP4F12)

Target: CYP4F12
Molecular classification: Enzyme, Cytochrome P450 monooxygenase, Oxidoreductase

Overview

Cytochrome P450 family 4 subfamily F member 12 (CYP4F12) is a member of the cytochrome P450 superfamily of enzymes, which are monooxygenases involved in the metabolism of a variety of endogenous polyunsaturated fatty acids and xenobiotic compounds, including drugs and toxins. CYP4F12 localizes to the endoplasmic reticulum and catalyzes hydroxylation and epoxidation reactions, such as oxidation of arachidonic acid and the antihistamine ebastine. CYP4F12 plays a multifaceted role in lipid metabolism and the biotransformation of pharmaceuticals, and recent evidence implicates it in cancer biology, particularly as a negative regulator of epithelial-mesenchymal transition (EMT) and cell migration in head and neck squamous cell carcinoma. Differential expression of CYP4F12 can serve as a biomarker for cancer prognosis, and its enzymatic activity underpins both its physiological and potential therapeutic significance [1][2][3][7].

Other names: Cytochrome P450 4F12CYPIVF12F22329_1UNQ568/PRO1129

Mechanism of action

Substrate oxidation (catalyzes hydroxylation and epoxidation); Metabolizes both endogenous substrates (arachidonic acid, docosahexaenoic acid, docosapentaenoic acid) and xenobiotics (such as drugs); Modulates fatty acid-derived signaling molecules

Biological functions

Drug metabolismFatty acid (lipid) metabolismHydroxylation and epoxidation of polyunsaturated fatty acidsMetabolism of xenobioticsEpoxygenase activityInhibition of cell migration (via EMT modulation in cancer)Potential roles in immune regulation and apoptosis in tumor context

Disease associations

Cancer (e.g., head and neck squamous cell carcinoma)Possibly other conditions related to lipid mediator metabolism and drug metabolismOther (as CYP450 enzymes are broadly involved in various diseases, but cancer has the clearest evidence for a disease-specific role)

Safety considerations

Drug–drug interactions due to its role in drug metabolism (variation in CYP4F12 expression or activity could alter drug efficacy or toxicity)Potential off-target effects or unintended modulation of fatty acid metabolism if pharmacologically targeted

Interacting drugs

Ebastine (antihistamine; metabolized by CYP4F12)

1 more in the full profile.

Biomarkers

CYP4F12 expression is proposed as a prognostic and predictive biomarker for head and neck squamous cell carcinoma (HNSC), especially with regard to tumor progression and immune infiltration

Beyond the preview

Go deeper on Cytochrome P450 family 4 subfamily F member 12 (CYP4F12).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cytochrome P450 family 4 subfamily F member 12 (CYP4F12).

Explore the full profile